v3.26.1
SEGMENT REPORTING
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
SEGMENT REPORTING

NOTE 15 – SEGMENT REPORTING

 

Operating segments are components of an enterprise about which separate financial information is available and is evaluated regularly by management, namely the Chief Operating Decision Maker (“CODM”) of an organization, in order to determine operating and resource allocation decisions. By this definition, the Company has identified its Chief Executive Officer as the CODM. Effective in 2024, the Company began operating in two segments: Biotechnology and Technology. Prior to 2024, the Company did not report operating segments.

 

Biotechnology Segment: This segment is non-revenue generating and incurs expenses by developing its biotechnology product pipeline. The Biotechnology Segment had total assets of $18,273,736 and $13,783,575 as of March 31, 2026 and December 31, 2025, respectively.

 

Technology Segment: This segment is revenue generating and incurs expenses by acquiring technology assets to support and enhance operational capabilities through advanced technologies. The Technology Segment had total assets of $1,512,957 and $2,370,346 as of March 31, 2026 and December 31, 2025, respectively. 

 

The Company believes that this structure reflects its current operational and financial management, and that it provides the best structure for the Company to focus on growth opportunities while maintaining financial discipline. The factors used to identify the Biotechnology and Technology operating segments were the difference in future potential revenue streams and customer base for each segment, the reporting structure for operational and performance information within the Company, and management’s decision to organize the Company around the different future potential revenue generating activities of the segments.

 

Segment information relating to the Company’s two operating segments for the three months ended March 31, 2026 and 2025 is as follows:

            
  

Three Months Ended

March 31, 2026

 
  

Biotechnology

Segment

   Technology
Segment		   Consolidated 
Sales  $–   $113,771   $113,771 
Cost of goods sold   –    45,156    45,156 
Total operating expenses   3,870,396    112,683    3,983,259 
Net loss from operations  $(3,870,396)  $(44,248)  $(3,914,644)

 

  

Three Months Ended

March 31, 2025

 
  

Biotechnology

Segment

  

Technology

Segment

   Consolidated 
Sales  $–   $62,874   $62,874 
Cost of goods sold   –    45,156    45,156 
Total operating expenses   4,014,702    60,000    4,074,702 
Net loss from operations  $(4,014,702)  $(42,282)  $(4,056,984)